Google’s biotech venture hit by ethical concerns over deal with luxury clinic
By Charles Piller,
STAT
| 04. 07. 2016
Untitled Document
MOUNTAIN VIEW, Calif. — Andrew Conrad, who runs Google’s ambitious biotech offshoot, successfully pushed the company to award a research contract to a luxury health clinic he largely owns that has no documented experience with this kind of work, STAT has learned. The arrangement has stirred concern inside Verily Life Sciences — and among corporate governance experts who see it as a conflict of interest.
Verily is also marketing to pharmaceutical companies a wealth of data on volunteers who participate in its major health study, called Baseline. It’s unclear whether Verily has informed volunteers of its plans to profit on their health data; the company declined to provide a copy of the consent agreement for volunteers tested at Conrad’s clinic.
Continue reading...
Image via Wikimedia
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.30.2026
A research program at the National Institutes of Health released the world’s largest database of human genomes and paired them with clinical data, officials announced Tuesday, paving the way for a new era of study in personalized medicine.
The All...
By Editorial Staff, The Guardian | 07.05.2026
Ever since Crispr-Cas9 gene-editing technology emerged in the early 2010s, ethical questions around genetically altered humans, so-called designer babies, have become increasingly urgent. There is already a worldwide legal prohibition. No country currently allows human germline editing (meaning genetic changes...
By Sarah Norcross, Sandy Starr, Amanda Cooney, and Anneliese Burton, BioNews | 07.06.2026
By Anna Louie Sussman, The New York Times | 07.01.2026
Birthrates in much of the developed world are at record lows, but there’s one demographic group that’s exploring new frontiers of fertility: ultrawealthy men. Deploying nearly limitless resources, a small number of them are reproducing at such an extraordinary scale...